RecruitingNCT06751082
Real World Observational Study of Sotatercept for Pulmonary Hypertension
Sotatercept Pulmonary Hypertension Observational Registry
Sponsor
Mayo Clinic
Enrollment
120 participants
Start Date
Jan 20, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study seeks to describe the real world initial experience with sotatercept in the treatment of pulmonary hypertension.
Eligibility
Min Age: 18 Years
Inclusion Criteria1
- Adults age 18 or greater who are being treated with sotatercept in the Mayo Pulmonary hypertension clinic.
Exclusion Criteria1
- Adults lacking capacity to consent
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06751082
Related Trials
A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489
NCT0707382044 locations
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT0638842162 locations
NeoDoppler: New Ultrasound Technology for Continuous Monitoring of Cerebral Circulation Pilot
NCT066462501 location
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
NCT073331831 location
iTONE Trial (exercIse Training in pulmONary hypertEnsion) Exercise Program for Pediatric PH
NCT054426711 location